Celldex Therapeutics (CLDX) Income from Continuing Operations (2010 - 2026)
Celldex Therapeutics' (CLDX) quarterly Income from Continuing Operations came in at 85903000.0 in Q1 2026, down 37.12% year-on-year from 136604892.5 in Q1 2025, and up 21.63% quarter-over-quarter from 109619000.0 in Q4 2025.
Celldex Therapeutics (CLDX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 85903000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 37.12% year-over-year to 85903000.0 in Q1 2026; TTM through Mar 2026 was 326773000.0, a 34.59% increase from a year earlier, with the FY2025 full-year figure at 661560000.0, down 38.51% from the prior year.
- Income from Continuing Operations rose to 85903000.0 in Q1 2026 per CLDX's latest filing, from 109619000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 23050000.0 in Q1 2022 and bottomed at 390692000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 47734000.0 (2024), against an average of 87009235.29.
- Across the five-year window, Income from Continuing Operations tumbled 1375.03% in 2023 and jumped 67.81% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 26487000.0 in 2022, then tumbled by 1375.03% to 390692000.0 in 2023, then rose by 12.83% to 340548000.0 in 2024, then soared by 67.81% to 109619000.0 in 2025, then increased by 21.63% to 85903000.0 in 2026.
- Per Business Quant, the three latest CLDX Income from Continuing Operations figures stand at 85903000.0 (Q1 2026), 109619000.0 (Q4 2025), and 67047000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Celldex Therapeutics | 2.34 Bn | 2.34 Bn | -1.44 Mn | -85.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.90 Mn |
| Dec 31, 2025 | -109.62 Mn |
| Sep 30, 2025 | -67.05 Mn |
| Jun 30, 2025 | -64.20 Mn |
| Mar 31, 2025 | -62.65 Mn |
| Dec 31, 2024 | -340.55 Mn |
| Sep 30, 2024 | -48.63 Mn |
| Jun 30, 2024 | -47.73 Mn |
| Mar 31, 2024 | -42.24 Mn |
| Dec 31, 2023 | -390.69 Mn |
| Sep 30, 2023 | -41.64 Mn |
| Jun 30, 2023 | -33.78 Mn |
| Mar 31, 2023 | -32.14 Mn |
| Dec 31, 2022 | -26.49 Mn |
| Sep 30, 2022 | -26.78 Mn |
| Jun 30, 2022 | -36.00 Mn |
| Mar 31, 2022 | -23.05 Mn |
| Dec 31, 2021 | -20.15 Mn |
| Sep 30, 2021 | -20.45 Mn |
| Jun 30, 2021 | -13.37 Mn |